-
Mashup Score: 42[68Ga]Ga-FAPI-46 False-Positive Uptake After Chemotherapy in Nonseminomatous Germ Cell Tumor Metastatic Lesions - 10 day(s) ago
A 38-y-old man with mixed, nonseminomatous germ cell carcinoma metastatic to the lung, liver, and retroperitoneal lymph nodes was treated with left orchiectomy and 4 cycles of cisplatin, etoposide, and ifosfamide. CT performed 3 d after the end of the last cycle showed significant improvement but
Source: jnm.snmjournals.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 7
Prostate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers. In this Commission, we report projections of prostate cancer cases in 2040 on the basis of data for demographic changes worldwide and rising life expectancy. Our findings suggest that the number of new cases annually will rise from 1·4 million in 2020 to 2·9 million by 2040. This surge in cases cannot be prevented by lifestyle changes or public health interventions alone, and governments need to prepare strategies to deal with it.
Source: www.thelancet.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 39
Posttreatment imaging of γ-emissions after peptide receptor radionuclide therapy (PRRT) can be used to perform quantitative dosimetry as well as assessment response using qualitative measures. We aimed to assess the impact of qualitative posttreatment imaging on the management of patients undergoing PRRT. Methods: In this retrospective study, we evaluated 100 patients with advanced well-differentiated neuroendocrine tumors undergoing PRRT, who had posttreatment SPECT/CT imaging at 24 h. First, we evaluated the qualitative assessment of response at each cycle. Then using a chart review, we determined the impact on management from the posttreatment imaging. The changes in management were categorized as major or minor, and the cycles at which these changes occurred were noted. Additionally, tumor grade was also evaluated. Results: Of the 100 sequential patients reviewed, most (80% after cycle 2, 79% after cycle 3, and 73% after cycle 4) showed qualitatively stable disease during PRRT. Man
Source: jnm.snmjournals.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4Theranostics treatments for cancer underway at UCLA Health - 1 month(s) ago
Targeted radioactive drugs are used to treat patients with advanced prostate, thyroid and neuroendocrine cancer.
Source: www.uclahealth.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 91
Both imaging and several prognostic factors inform the planning of salvage radiotherapy (SRT). Prostate-specific membrane antigen positron emission to…
Source: www.sciencedirect.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 52
These results support the use of [177Lu]Lu-PSMA-617 as an alternative to cabazitaxel for PSMA-positive metastatic castration-resistant prostate cancer progressing after docetaxel. We did not find evidence that overall survival differed between the randomised groups. Median overall survival was shorter for men who were excluded because of low PSMA expression or 2-[18F]FDG-discordant disease.
Source: www.thelancet.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 52
These results support the use of [177Lu]Lu-PSMA-617 as an alternative to cabazitaxel for PSMA-positive metastatic castration-resistant prostate cancer progressing after docetaxel. We did not find evidence that overall survival differed between the randomised groups. Median overall survival was shorter for men who were excluded because of low PSMA expression or 2-[18F]FDG-discordant disease.
Source: www.thelancet.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 61Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer - 5 month(s) ago
Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS) BEDFORD,…
Source: www.globenewswire.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 61Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer - 5 month(s) ago
Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS) BEDFORD,…
Source: www.globenewswire.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 50
These results support the use of [177Lu]Lu-PSMA-617 as an alternative to cabazitaxel for PSMA-positive metastatic castration-resistant prostate cancer progressing after docetaxel. We did not find evidence that overall survival differed between the randomised groups. Median overall survival was shorter for men who were excluded because of low PSMA expression or 2-[18F]FDG-discordant disease.
Source: www.thelancet.comCategories: General Medicine News, Partners & KOLsTweet
⚠️Beware of False-Positive Uptake on FAPI and FDG PET even 3 months After Chemotherapy in Non-Seminomatous Germ Cell Tumor ! It can be just fibronecrotic tissue. #PET #FAPI #FDG #theranostics #CancerResearch https://t.co/UVAA42RgNV https://t.co/CaCv3oFsT2